Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other high potential preclinical projects Regulatory News: Lysogene (FR0013233475 LYS) (Paris:LYS)
The financing will enable Lysogene to accelerate the development of its gene therapy platform The loan consists of three tranches including a first unconditional tranche of €3 million The.
26.11.2021 - Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has secured a €4.3 million non-dilutive financing from Bpifrance. This .